Molnupiravir: A new candidate for COVID‐19 treatment
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee
Abstract
The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with anti-RNA polymerase activity and currently is under investigation for the treatment of patients with COVID-19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID-19 patients.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MedicinePharmacotherapySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakClinical trialIntensive care medicineCoronavirusPandemicFavipiravirDiseaseVirologyInternal medicineOutbreakInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research